Literature DB >> 6128421

Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.

E H Gold, W Chang, M Cohen, T Baum, S Ehrreich, G Johnson, N Prioli, E J Sybertz.   

Abstract

A useful method for the separation of labetalol into its two racemic diastereomers, as well as a stereoselective synthesis of its four stereoisomers, is described. The absolute stereochemistry of each isomer was determined by analysis of the DC spectra and confirmed by X-ray analysis. The alpha- and beta 1-adrenergic blocking properties, as well as the relative antihypertensive activities, have been measured in rats. The R,R isomer, 2a (SCH 19927), possesses virtually all of the beta 1-blocking activity elicited by labetalol and displays little alpha-blocking activity. In contrast, the S,R isomer, 3a, has most of the alpha-blocking activity. Of the four isomers, only 2a has antihypertensive potency comparable to that of labetalol. These findings, coupled with published data showing that labetalol possesses beta-adrenergic mediated peripheral vasodilating activity deriving essentially from its R,R isomer, lead to the following conclusion: The antihypertensive activity of labetalol can be ascribed to at least three identified complementary mechanisms, beta-adrenergic blockade, beta-adrenergic mediated vasodilatation, and alpha-adrenergic blockade, whereas the antihypertensive activity of 2a derives from the first two mechanisms only.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128421     DOI: 10.1021/jm00353a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Theoretical and experimental exploration of the lipophilicity of zwitterionic drugs in the 1,2-dichloroethane/water system.

Authors:  Géraldine Bouchard; Alessandra Pagliara; Pierre-Alain Carrupt; Bernard Testa; Véronique Gobry; Hubert H Girault
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

2.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 3.  Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

6.  Effects of dilevalol in the anesthetized pig with a partially occluded coronary artery.

Authors:  M O den Boer; L M Sassen; W J van der Giessen; P R Saxena; P D Verdouw
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

Review 7.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

9.  Labetalol facilitates GABAergic transmission to rat periaqueductal gray neurons via antagonizing beta1-adrenergic receptors--a possible mechanism underlying labetalol-induced analgesia.

Authors:  Cheng Xiao; Chunyi Zhou; Glen Atlas; Ellise Delphin; Jiang Hong Ye
Journal:  Brain Res       Date:  2008-01-18       Impact factor: 3.252

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.